文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

保守氧疗在ICU机械通气成人患者中的应用:UK-ROX随机临床试验

Conservative Oxygen Therapy in Mechanically Ventilated Critically Ill Adult Patients: The UK-ROX Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在ICU机械通气成人患者中,以SpO2 90%(88%-92%)为目标的保守氧疗未显著降低90天全因死亡率(风险差0.7个百分点,95%CI -0.7至2.0,P=.28)。

UK-ROX多中心随机试验纳入英国97个ICU的16500例接受机械通气的成人患者,比较保守氧疗(SpO2目标90%,范围88%-92%,n=8258)与常规氧疗(由临床医生决定,n=8242)。保守组补充氧暴露较常规组低29%。90天全因死亡率保守组35.4% vs 常规组34.9%,校正后风险差0.7个百分点(95%CI -0.7至2.0;P=.28)。ICU及急性住院时间、30天无器官支持存活天数及其他时间点死亡率均无显著差异。

要点

  • 在16500例ICU机械通气成人中,保守氧疗(SpO2目标90%,88%-92%)较常规氧疗未显著降低90天全因死亡率:35.4% vs 34.9%,校正后风险差0.7个百分点(95%CI -0.7至2.0;P=.28)。
  • 保守组补充氧暴露较常规组低29%,但ICU及急性住院时间、30天无器官支持存活天数、其他时间点死亡率均无显著差异。
  • 研究为多中心、实效性随机试验,在英国97个ICU开展,2021年5月至2024年11月入组,随访至2025年2月完成。
  • 两组基线相似:中位年龄60岁(IQR 48-71),女性占38.2%(n=5652)。

适用人群与场景

  • 英国97个ICU中接受机械通气并补充氧疗的成人患者,2021年5月至2024年11月入组,随访至2025年2月完成。

诊断标准与关键阈值

  • 保守氧疗组:使用尽可能低的吸入氧浓度维持SpO2在90%(范围88%-92%)。

处置流程与药物剂量

  • 保守氧疗组(n=8258):使用尽可能低的吸入氧浓度维持SpO2在90%(范围88%-92%)。
  • 常规氧疗组(n=8242):由治疗临床医生酌情给予氧疗。

研究设计与关键结果

  • 多中心、实效性随机临床试验,纳入英国97个ICU的16500例机械通气成人患者,保守氧疗组n=8258,常规氧疗组n=8242。
  • 主要终点90天全因死亡率:保守组2908例(35.4%)死亡,常规组2858例(34.9%)死亡;校正预设基线变量后风险差0.7个百分点(95%CI -0.7至2.0;P=.28)。
  • 保守组补充氧暴露较常规组低29%。
  • ICU及急性住院时间、30天无器官支持存活天数、其他时间点死亡率均无显著差异。
  • 基线:中位年龄60岁(IQR 48-71),女性38.2%(n=5652),两组相似。

证据类型、等级与局限

  • 研究类型:多中心、实效性随机临床试验。
  • 试验注册:isrctn.org标识符ISRCTN13384956。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU机械通气成人患者中,采用SpO2目标90%(范围88%-92%)的保守氧疗策略未显著降低90天全因死亡率,也未显著改变ICU及住院时间、30天无器官支持存活天数及其他时间点死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Supplemental oxygen is frequently given to patients in intensive care units (ICUs); however, there is insufficient evidence to guide its therapeutic use and to minimize the potential harm caused by administering too little or too much.

OBJECTIVE: To determine whether reducing exposure to supplemental oxygen through a strategy of conservative oxygen therapy by using a peripheral oxygen saturation (Spo2) target of 90% (range, 88%-92%) reduces mortality at 90 days in mechanically ventilated adult patients receiving supplemental oxygen in the ICU.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter, pragmatic, randomized clinical trial conducted in 97 ICUs in the UK including 16 500 mechanically ventilated patients receiving supplemental oxygen. Participants were enrolled between May 2021 and November 2024. Follow-up was completed in February 2025.

INTERVENTIONS: Participants randomized to conservative oxygen therapy (n = 8258) received the lowest fraction of inspired oxygen possible to maintain their Spo2 at 90%. Participants randomized to usual oxygen therapy (n = 8242) received oxygen therapy at the discretion of the treating clinician.

MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 90 days. Secondary outcomes included duration of ICU and acute hospital stay among survivors, days alive and free from organ support at 30 days, and mortality at other time points.

RESULTS: Of 16 500 randomized patients, primary outcome data were available for 16 394 (8211 in the conservative and 8183 in the usual oxygen therapy group). Randomized groups were similar (median age, 60 [IQR, 48-71] years and 38.2% females in both groups [n = 5652]). Exposure to supplemental oxygen was 29% lower for participants in the conservative oxygen therapy group compared with the usual oxygen therapy group. By 90 days, 2908 participants (35.4%) in the conservative oxygen therapy group had died compared with 2858 (34.9%) in the usual oxygen therapy group. After adjustment for prespecified baseline variables, the risk difference was 0.7 percentage points (95% CI, -0.7 to 2.0; P = .28). There were no significant differences in durations in ICU or hospital stay, days alive and free from organ support at 30 days, or mortality at other time points.

CONCLUSIONS AND RELEVANCE: In adult patients receiving mechanical ventilation and supplemental oxygen in the ICU, minimizing oxygen exposure through conservative oxygen therapy did not significantly reduce all-cause mortality at 90 days.

TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN13384956.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Martin DS, Gould DW, Shahid T, et al. Conservative Oxygen Therapy in Mechanically Ventilated Critically Ill Adult Patients: The UK-ROX Randomized Clinical Trial. JAMA. 2025. PMID: 40501321. doi:10.1001/jama.2025.9663

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。